{"slug":"ara-290-post-surgical-nerve","verification":{"valid":true,"entries":21,"head":"d717a3a1c20692231c7f4f244a2cb9c25b4789f2974fd749d613b10697ee2aab"},"count":21,"models":["grok/grok-4.3","grok-4.3","system/audit-repair","kimi/moonshot-v1-8k","gemini/gemini-2.5-flash","fill-slots"],"yield":{"passes":21,"energy_spent_rows":0,"total_cost_usd":0.013315,"waste_cost_usd":0,"total_tokens":19087,"material_outputs":8,"usd_per_output":0.001664,"models":[{"model":"kimi/moonshot-v1-8k","passes":2,"cost_usd":0.001096,"tokens_total":7306,"outputs":6,"waste_passes":0,"usd_per_output":0.000183},{"model":"gemini/gemini-2.5-flash","passes":1,"cost_usd":0.000327,"tokens_total":3283,"outputs":2,"waste_passes":0,"usd_per_output":0.000163},{"model":"grok-4.3","passes":9,"cost_usd":0,"tokens_total":0,"outputs":0,"waste_passes":0,"usd_per_output":null},{"model":"system/audit-repair","passes":5,"cost_usd":0,"tokens_total":0,"outputs":0,"waste_passes":0,"usd_per_output":null},{"model":"fill-slots","passes":2,"cost_usd":0,"tokens_total":0,"outputs":0,"waste_passes":0,"usd_per_output":null},{"model":"grok/grok-4.3","passes":2,"cost_usd":0.011893,"tokens_total":8498,"outputs":0,"waste_passes":0,"usd_per_output":null}],"constraints":{"constitution":"/api/articles/constitution","collaborate_schema":"POST /api/protocol/collaborate","pricing_ppm":{"grok-4.3":[1.25,2.5],"grok/grok-4.3":[1.25,2.5],"grok-build-0.1":[1,2],"kimi/moonshot-v1-8k":[0.15,0.15],"gemini/gemini-2.5-flash":[0.075,0.3],"gemini/gemini-2.0-flash-lite":[0.075,0.3],"openai/gpt-4o":[2.5,10],"openai/gpt-4o-mini":[0.15,0.6],"system/reflex":[0,0],"ingest:deterministic":[0,0],"fill-slots":[0,0]}}},"contributions":[{"seq":0,"id":"k1","ts":"2026-06-29T08:55:10.467Z","model":"grok/grok-4.3","role":"writer","action":"redraft","payload":{"title":"ARA-290 for Post-Surgical Nerve Damage: Evidence Review","register":"source_ledger","body":"## Overview\n\nARA-290 (cibinetide) is an 11-amino-acid peptide selective agonist of the innate repair receptor (IRR), a heteromer of EPO receptor and β-common receptor subunits upregulated after tissue injury. Activation promotes anti-inflammatory and tissue-repair signaling without hematopoietic effects.\n\n## Human Clinical Data\n\nTwo randomized, double-blind, placebo-controlled trials in small-fiber neuropathy (SFN) associated with sarcoidosis reported symptom improvement on the Small Fiber Neuropathy Screening List after 28 days of 4 mg daily subcutaneous ARA-290, plus increased corneal nerve fiber density (CNFD) measured by in vivo confocal microscopy in one trial (human tier). A phase 2 trial in type 2 diabetes with painful neuropathy showed improved neuropathic symptoms on PainDetect questionnaire, HbA1c reduction, and CNFD increase in a subgroup with baseline reduction (human tier). No serious adverse effects linked to erythropoiesis were observed.\n\n## Relevance to Post-Surgical Nerve Damage\n\nNo human trials have evaluated ARA-290 specifically in post-surgical nerve injury or compression (no human data). Preclinical rat models of sciatic nerve crush or spared nerve injury demonstrate reduced allodynia and promotion of nerve repair via IRR activation (preclinical tier). Human SFN data used CNFD as a structural regeneration marker; epidermal nerve fiber density showed no change in the same studies.\n\n## Mechanistic Framing\n\nARA-290 targets IRR to shift from proinflammatory to repair milieu rather than masking pain signals (mechanistic tier). This differs from symptomatic analgesics.\n\n## Anecdotal Reports\n\nUser forums report off-label use following trial protocols (e.g., 4 mg daily), with variable self-reported outcomes on numbness or pain (anecdotal tier). No controlled verification.\n\n## Evidence Gaps\n\nDirect human data for surgical contexts, long-term outcomes, and epidermal versus corneal regeneration consistency are absent. All cited human trials involve non-surgical SFN etiologies.","claims":[{"id":"c1","text":"Human trials in sarcoidosis SFN showed symptom improvement and increased corneal nerve fiber density after 28 days of ARA-290.","section":"Human Clinical Data","tier":"human","source_ids":["s1","s2"],"source_status":"sourced","why_material":"Direct evidence of structural nerve fiber changes in humans","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"extra":{}},{"id":"c2","text":"Human trial in type 2 diabetes neuropathy showed improved neuropathic symptoms and CNFD increase in subgroup.","section":"Human Clinical Data","tier":"human","source_ids":["s3"],"source_status":"sourced","why_material":"Additional human data on symptom and structural outcomes","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"extra":{}},{"id":"c3","text":"No human trials have tested ARA-290 in post-surgical nerve damage.","section":"Relevance to Post-Surgical Nerve Damage","tier":"human","source_ids":["s4"],"source_status":"sourced","why_material":"Clarifies evidence gap for the target population","evidence_basis":"derived_inference","weight":0.8,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"extra":{}},{"id":"c4","text":"Rat models of sciatic nerve injury show reduced allodynia and nerve repair effects with ARA-290.","section":"Relevance to Post-Surgical Nerve Damage","tier":"preclinical","source_ids":["s5"],"source_status":"sourced","why_material":"Provides mechanistic mapping to surgical injury models","evidence_basis":"derived_inference","weight":0.5,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"extra":{}},{"id":"c5","text":"ARA-290 activates IRR to promote anti-inflammatory and repair pathways rather than symptomatic pain masking.","section":"Mechanistic Framing","tier":"mechanistic","source_ids":["s1"],"source_status":"sourced","why_material":"Distinguishes repair mechanism from suppression","evidence_basis":"derived_inference","weight":0.3,"status":"active","stance_scores":{"neutral":0,"pro":0,"adversary":0},"extra":{}}],"sources":[{"id":"s1","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC5741312/","title":"Targeting the innate repair receptor to treat neuropathy","quote":"In patients with sarcoidosis, ARA290 significantly improved neuropathic and autonomic symptoms... In addition, ARA290 treatment for 28 days initiated a regrowth of small nerve fibers in the cornea...","link_status":"ok","quote_status":"unverified"},{"id":"s2","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/24136731/","title":"ARA 290 improves symptoms in patients with sarcoidosis-associated small nerve fiber loss and increases corneal nerve fiber density","quote":"28 d of daily subcutaneous administration of ARA 290... significantly improves neuropathic symptoms... significant increase in corneal small nerve fiber density","link_status":"ok","quote_status":"unverified"},{"id":"s3","type":"pubmed","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/","title":"ARA 290... Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes","quote":"Neuropathic symptoms as assessed by the PainDetect questionnaire improved significantly... subjects with a mean CNFD >1 standard deviation from normal showed a significant increase in CNFD","link_status":"ok","quote_status":"unverified"},{"id":"s4","type":"other","url":"https://www.truehealwellness.com/peptides-research/ara-290","title":"ARA-290: Neuropathic Pain & Nerve Repair","quote":"For post-surgical nerve pain, the rationale is preclinical (an animal surgical-nerve-injury study); no human trial has tested it.","link_status":"ok","quote_status":"verified"},{"id":"s5","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/25549226/","title":"Discovery of a master regulator of injury and healing","quote":"ARA 290 has effective and prolonged (up to 20 weeks) anti-allodynic effects... after nerve injury","link_status":"ok","quote_status":"unverified"}]},"rationale":"","tokens_in":0,"tokens_out":0,"prev_hash":"genesis","hash":"f9fe221069229e26e938647941347662c12427e064dc2c70bc0baca8259fac6f"},{"seq":1,"id":"k2","ts":"2026-06-29T10:37:17.363Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s6","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/21873879/","title":"ARA290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response","quote":"ARA290 is a promising new drug in the prevention of peripheral nerve injury -induced neuropathic pain in humans.","link_status":"ok","quote_status":"unverified"},{"id":"s7","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/24529189/","title":"ARA 290, a peptide derived from the tertiary structure of erythropoietin, produces long-term relief of neuropathic pain coupled with suppression of the spinal microglia response","quote":"Following a spared nerve injury in rats, vehicle or ARA290 (administered in either one of 4 doses: 3, 10, 30 and 60 μg/kg) was administered on days 1, 3, 6, 8 and 10.","link_status":"ok","quote_status":"verified"},{"id":"s8","type":"clinical_trial","url":"https://clinicaltrials.gov/study/NCT02039687","title":"Study of Efficacy of ARA 290 on Corneal Nerve Fiber Abundance in Patients With Sarcoidosis","quote":"The purpose of this study is to determine whether ARA 290 , a new class of compound, is effective in the treatment of the neuropathic symptoms of sarcoidosis ...","link_status":"ok","quote_status":"unverified"},{"id":"s9","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/23262243/","title":"The erythropoietin-derived peptide ARA290 reverses established neuritic dystrophy in Akita (Ins2Akita) diabetic mouse sympathetic ganglia","quote":"ARA290 may be beneficial in the treatment of neuropathic pain symptoms where signs of nerve injury are absent on clinical assessment.","link_status":"ok","quote_status":"verified"},{"id":"s10","type":"reddit","url":"https://www.reddit.com/r/smallfiberneuropathy/comments/v44s3q/effectiveness_of_ara290my_assessment/","title":"Effectiveness of ARA-290...My Assessment","quote":"I followed the clinical phase II protocol from 2017. 28 days, 4mg/day... Definite benefit, although it took12 days for it to start working... Slight improvement in numbness.","link_status":"ok","quote_status":"unverified"},{"id":"s11","type":"reddit","url":"https://www.reddit.com/r/neuropathy/comments/1o33123/peptide_ara290/","title":"Peptide ARA-290","quote":"Has anyone tried the peptide ARA-290. It has clinical evidence of helping to slow or stop neuropathy and allow nerves to heal.","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"prev_hash":"f9fe221069229e26e938647941347662c12427e064dc2c70bc0baca8259fac6f","hash":"1dc51f4e46c70fd2676c9bf415c3a444031aa818d794e7db3cd1aa2f151907a4"},{"seq":2,"id":"k3","ts":"2026-06-29T10:37:41.830Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s12","type":"review","url":"https://www.sciencedirect.com/science/article/abs/pii/S1567576924009731","title":"The protective effect of erythropoietin and its novel derived peptides in peripheral nerve injury","quote":"This review summarizes for the first time the role of ARA290 and CHBP, derivatives of EPO in peripheral nerve injury.","link_status":"http_403","quote_status":"unverified"},{"id":"s13","type":"medical","url":"https://alphacarbonlabs.com/blog/peripheral-nerve-regeneration-the-synergistic-potential-of-ara-290-and-bpc-157-in-neuropathic-research","title":"Healing Nerve Damage: ARA-290 and BPC-157","quote":"Post-Surgical Recovery. Surgery inevitably cuts through nerves.","link_status":"ok","quote_status":"unverified"},{"id":"s14","type":"reddit","url":"https://www.reddit.com/r/neuropathy/comments/1tncdyo/ara290_peptide_and_rebuilder_2407_have_changed_my/","title":"ARA290 peptide AND Rebuilder 2407 have changed my life!","quote":"I am at 8 days of the ARA290 peptide and have titrated up to the 4 mg used in the human trials. ... Yesterday was by FAR the best day of the past 15 months! I walked over 14,000 steps pain free!","link_status":"ok","quote_status":"unverified"},{"id":"s15","type":"reddit","url":"https://www.reddit.com/r/smallfiberneuropathy/comments/1ce0ub5/do_i_have_sfn_ara290_helped/","title":"Do I have SFN? ARA-290 helped","quote":"I tried the peptide ARA-290 because it was supposed to help with nerve re-growth. It was amazing! Feeling started to come back...","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"prev_hash":"1dc51f4e46c70fd2676c9bf415c3a444031aa818d794e7db3cd1aa2f151907a4","hash":"965e49e5e62bd3e872b8485d0dd08f488035b349ba49099b9d8dc481a65d16fd"},{"seq":3,"id":"k4","ts":"2026-06-29T10:38:05.410Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s16","type":"reddit","url":"https://www.reddit.com/r/neuropathy/comments/hreepv/ara290_peptide_any_experience_reports/","title":"ARA-290 peptide — any experience reports?","quote":"I am 55 years old ... I had L5/S1 anterior back surgery about 4 yrs ago. Unfortunately, one of the side effects to my surgery was the potential non-diabetic peripheral neuropathy which I ended up getting. ... I started doing research and I learned about ARA 290 which I purchased through Peptides Sciences ... I'm on my second shot so far so perhaps it's too soon to opine. ... So far so good! ... I have no side effects, such as headaches, itchiness on the injection site or any other of the minimal side effects per the studies.","link_status":"ok","quote_status":"unverified"},{"id":"s17","type":"reddit","url":"https://www.reddit.com/r/neuropathy/comments/hreepv/ara290_peptide_any_experience_reports/","title":"ARA-290 peptide — any experience reports?","quote":"I am almost done with a month of ara 290. ... It’s not cheap. I have seen really great results. My neuropathy was very bad and it has improved significantly. I have tried almost everything and this was the most helpful by far. Whether it lasts I’ll have to see.","link_status":"ok","quote_status":"unverified"},{"id":"s18","type":"reddit","url":"https://www.reddit.com/r/neuropathy/comments/hreepv/ara290_peptide_any_experience_reports/","title":"ARA-290 peptide — any experience reports?","quote":"I began last week at .5 mg, then 1, then 2, then 3 and finally 4 mg. ... I quickly developed painful tingling around the outside of both feet at 2 mg. Those last 3 days were very painful. ... I have been off the peptide for 2 days now and the pain is mostly gone.","link_status":"ok","quote_status":"unverified"},{"id":"s19","type":"reddit","url":"https://www.reddit.com/r/smallfiberneuropathy/comments/vlbxty/ara290_for_neuropathic_pain/","title":"ARA-290 for Neuropathic Pain","quote":"I’ve taken it it helps with pain but it’s temporary. You have to keep doing it from time to time at least and it’s expensive.","link_status":"ok","quote_status":"unverified"},{"id":"s20","type":"reddit","url":"https://www.reddit.com/r/neuropathy/comments/1tvw5x6/ara290_disc_herniaton_nerve_pain/","title":"ARA-290 Disc Herniaton & Nerve Pain","quote":"I’ve been dealing with pretty annoying nerve pain from a herniated disc at C6–C7 ... I’ve started ARA-290 ... UPDATE (07.06.2026) I had to take 2 days off from it as I was abroad ... I was on it for less than a week and didn't notice any benefits nor side effects.","link_status":"ok","quote_status":"unverified"},{"id":"s21","type":"x","url":"https://x.com/RickWingfield5/status/2070195807316246840","title":"X post on ARA-290 for nerve pain","quote":"PEG-MGF has been incredible with healing my mid sixties muscles and ARA-290 is amazing for nerve pain in neck and shoulders.","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 3","tokens_in":0,"tokens_out":0,"prev_hash":"965e49e5e62bd3e872b8485d0dd08f488035b349ba49099b9d8dc481a65d16fd","hash":"283c77014ca0e2ca181f5d76b1bb93827b9763917915eff6ad9a40a9a4d9534a"},{"seq":4,"id":"k5","ts":"2026-06-29T10:38:30.464Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s22","type":"pubmed","url":"https://pubmed.ncbi.nlm.nih.gov/40216181/","title":"ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury","quote":"EPO and ARA290 promote repair and regeneration by inhibiting the activation of NLRP3 inflammasome after sciatic nerve injury.","link_status":"ok","quote_status":"verified"},{"id":"s23","type":"medical","url":"https://www.sciencedirect.com/science/article/abs/pii/S0014299925003644","title":"ARA290, an alternative of erythropoietin, inhibits activation of NLRP3 inflammasome in schwann cells after sciatic nerve injury","quote":"In our study, we demonstrated that both EPO and pyroglutamic acid helix B surface peptide (pHBSP, also known as ARA290) inhibit the early inflammatory response and promote functional recovery after sciatic nerve crush injury in rat models.","link_status":"http_403","quote_status":"unverified"},{"id":"s24","type":"reddit","url":"https://www.reddit.com/r/IonPeptideGuide/comments/1s0nyps/ara290_quick_guide_the_erythropoietinderived/","title":"ARA-290 Quick Guide: The Erythropoietin-Derived Peptide Targeting Neuropathic Pain and Tissue Protection","quote":"It has entered Phase I and Phase II human clinical trials for neuropathic pain (specifically in sarcoidosis patients), diabetic neuropathy, and critical limb ischemia","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 4","tokens_in":0,"tokens_out":0,"prev_hash":"283c77014ca0e2ca181f5d76b1bb93827b9763917915eff6ad9a40a9a4d9534a","hash":"b9720ebcfe0dc508979e80e3224c0f50ee8e834311c15f5554eb670b30db469f"},{"seq":5,"id":"k6","ts":"2026-06-29T10:39:18.493Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s25","type":"review","url":"https://journals.lww.com/painrpts/fulltext/2016/08000/targeting_the_innate_repair_receptor_to_treat.2.aspx","title":"Targeting the innate repair receptor to treat neuropathy","quote":"After sciatic nerve injury, ARA290 produced a rapid and long-term relief of mechanical and cold allodynia in normal mice, but not in animals with a β-common receptor knockout phenotype. ... We tested ARA290 in the spared nerve injury (SNI) model in mice and rats. ... Animals were sham operated (blue) or received SNI and vehicle (grey) or SNI and 60 µg/kg ARA290 (red), both administered on days 1, 3, 6, 8, and 10 postsurgery (*P* < 0.0001 compared with vehicle).","link_status":"ok","quote_status":"verified"},{"id":"s26","type":"medical","url":"https://peptidefox.com/content/ara-290","title":"ARA-290 (Cibinetide): An EPO-Derived 11-Amino-Acid Peptide","quote":"The reason to think it would help here is preclinical. The closest evidence is a rat study of a surgical nerve injury, where ARA-290 relieved touch and cold hypersensitivity and the effect vanished without the receptor. ... Could ARA-290 help lingering nerve pain after surgery, like after an ACL reconstruction? Possibly, if the pain is genuinely from a nerve (tingling, touch sensitivity), which is common after knee surgery. But be clear on the evidence: the reason to expect benefit is preclinical (an animal surgical-nerve-injury study), and no human trial has tested post-surgical nerve pain.","link_status":"ok","quote_status":"unverified"},{"id":"s27","type":"medical","url":"https://mindbodyneurology.com/ara-290-peptide-neuropathy/","title":"ARA 290 Peptide for Neuropathy and Neurodegeneration","quote":"A 2025 study using an ARA 290 microneedle patch in a diabetic peripheral neuropathy rat model showed relief of mechanical pain and improved nerve structure... Several key studies focus on ARA 290 in this group. ... A randomized, double-blind pilot trial in sarcoidosis with SFN symptoms...","link_status":"ok","quote_status":"unverified"},{"id":"s28","type":"other","url":"https://www.renewyouth.com/ara-290-a-new-frontier-in-pain-relief-and-healing/","title":"ARA 290: A New Frontier in Pain Relief and Healing","quote":"Neuropathic Pain: This type of pain is caused by nerve damage... Research suggests ARA 290 can reduce these painful sensations... Small Fiber Neuropathy: ... ARA 290 may help to repair these small nerve fibers...","link_status":"ok","quote_status":"unverified"},{"id":"s29","type":"medical","url":"https://www.paragonsportsmedicine.com/peptides/ara-290","title":"ARA-290 Peptide | Inflammation & Nerve Support","quote":"The peptide has gained significant attention in regenerative medicine and neurology due to its demonstrated efficacy in treating diabetic neuropathy, chronic neuropathic pain, and inflammatory conditions through its unique mechanism of promoting neural repair and reducing inflammation. ... Application Diabetic Neuropathy Neuropathic Pain","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"prev_hash":"b9720ebcfe0dc508979e80e3224c0f50ee8e834311c15f5554eb670b30db469f","hash":"b7ea57830126d9f9841e782bd470877a6d037e3f12ea595980193210efb65613"},{"seq":6,"id":"k7","ts":"2026-06-29T10:39:43.211Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s30","type":"review","url":"https://superpower.com/guides/ara-290","title":"ARA-290 (Cibinetide): An EPO-Derived 11-Amino-Acid Peptide Targeting the Innate Repair Receptor","quote":"Phase II RCTs in sarcoidosis patients showed a placebo-corrected increase in corneal nerve fiber area of 697 μm²/mm² at day 28, but no Phase III trials were completed before Araim Pharmaceuticals closed.","link_status":"ok","quote_status":"verified"},{"id":"s31","type":"medical","url":"https://preferredregen.com/blog/benefits-of-ara290-peptide-a-simple-guide","title":"Benefits of ARA290 Peptide: A Simple Guide","quote":"ARA-290 has shown promise in helping with broader peripheral nerve damage recovery. For example, in a study on patients with sarcoidosis, a condition that can cause small fiber neuropathy, ARA-290 treatment significantly improved neuropathic symptoms and quality of life. This suggests its healing properties can be applied to various forms of nerve damage, including those from a sports injury.","link_status":"ok","quote_status":"verified"},{"id":"s32","type":"instagram","url":"https://www.instagram.com/reel/DTadVV3j11t/","title":"Nerve pain treatment is also possible with peptides. ARA-290","quote":"ARA-290 is an excellent treatment for patients with nerve pain such as neuropathy, tarsal tunnel, nerve injury or post operative nerve pain.","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"prev_hash":"b7ea57830126d9f9841e782bd470877a6d037e3f12ea595980193210efb65613","hash":"8f252dafa49e1b60e356d028d0add033a4b904885ba037db79024e19f8855cce"},{"seq":7,"id":"k8","ts":"2026-06-29T12:48:13.359Z","model":"system/audit-repair","role":"claim_post","action":"claim","payload":{"claim_id":"c33","tier":"system","text":"ARA-290 for Post-Surgical Nerve Damage: Evidence Review is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","who_claims":"miscsubjects protocol","source_ids":[],"slot":"what_it_is","posted_by":{"actor":"miscsubjects protocol","channel":"protocol/fill-slots","ts":"2026-06-29T12:48:13.359Z","model":"system/audit-repair","rationale":""}},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"8f252dafa49e1b60e356d028d0add033a4b904885ba037db79024e19f8855cce","hash":"4003ea03f8e78629565c18d208bd652c54155d5a05be0fe04a4ad5b625ec6989"},{"seq":8,"id":"k9","ts":"2026-06-29T12:48:13.466Z","model":"system/audit-repair","role":"claim_post","action":"claim","payload":{"claim_id":"c34","tier":"preclinical","text":"Per this ledger on ARA-290 for Post-Surgical Nerve Damage: Evidence Review: 18 scientific and 12 anecdotal sources are catalogued; 9 preclinical claim(s) summarize animal/cell literature in-catalogue.","who_claims":"miscsubjects ledger synthesis","source_ids":[],"slot":"what_is_known","posted_by":{"actor":"miscsubjects ledger synthesis","channel":"protocol/fill-slots","ts":"2026-06-29T12:48:13.466Z","model":"system/audit-repair","rationale":""}},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"4003ea03f8e78629565c18d208bd652c54155d5a05be0fe04a4ad5b625ec6989","hash":"7eceb18d104ba57ee2d149d8ca8d26c34fc2692ff529bb907d5d63489167b24c"},{"seq":9,"id":"k10","ts":"2026-06-29T12:48:13.514Z","model":"system/audit-repair","role":"claim_post","action":"claim","payload":{"claim_id":"c35","tier":"speculative","text":"Not established in this ledger: large randomized human trials for common marketed uses; long-term human safety beyond small pilots; condition-specific efficacy where only anecdotal or preclinical sources exist (explicit gaps remain in question graph).","who_claims":"miscsubjects gap analysis","source_ids":[],"slot":"what_is_unknown","posted_by":{"actor":"miscsubjects gap analysis","channel":"protocol/fill-slots","ts":"2026-06-29T12:48:13.514Z","model":"system/audit-repair","rationale":""}},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"7eceb18d104ba57ee2d149d8ca8d26c34fc2692ff529bb907d5d63489167b24c","hash":"74ceccb5cd402468c4ed610a534acfe57d8c5f0a3dd5352198043e7257ce8359"},{"seq":10,"id":"k11","ts":"2026-06-29T12:48:13.671Z","model":"system/audit-repair","role":"claim_post","action":"claim","payload":{"claim_id":"c36","tier":"mechanistic","text":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","who_claims":"miscsubjects protocol","source_ids":[],"slot":"limitations","posted_by":{"actor":"miscsubjects protocol","channel":"protocol/fill-slots","ts":"2026-06-29T12:48:13.671Z","model":"system/audit-repair","rationale":""}},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"74ceccb5cd402468c4ed610a534acfe57d8c5f0a3dd5352198043e7257ce8359","hash":"a6c3b125374f7ffa7eecbb1c809efe65ca9dadece2e8ab6d851d5ca8ac3516c0"},{"seq":11,"id":"k12","ts":"2026-06-29T12:48:13.752Z","model":"system/audit-repair","role":"claim_post","action":"claim","payload":{"claim_id":"c37","tier":"human","text":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.","who_claims":"miscsubjects protocol","source_ids":[],"slot":"disclaimer","posted_by":{"actor":"miscsubjects protocol","channel":"protocol/fill-slots","ts":"2026-06-29T12:48:13.752Z","model":"system/audit-repair","rationale":""}},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"a6c3b125374f7ffa7eecbb1c809efe65ca9dadece2e8ab6d851d5ca8ac3516c0","hash":"e147aa1b35ba6e5ae9e05f06e3c9d70379a45b5938a0442986aac0105a5c5478"},{"seq":12,"id":"k13","ts":"2026-06-29T13:25:13.435Z","model":"kimi/moonshot-v1-8k","role":"collaborator","action":"collaborate","payload":{"claims_added":["c38","c39"],"challenge_id":"c40","rationale":"I am adding explicit gaps in knowledge (what_is_unknown) and identifying anecdotal claimants (who_claims_what) to fulfill the instructions."},"rationale":"I am adding explicit gaps in knowledge (what_is_unknown) and identifying anecdotal claimants (who_claims_what) to fulfill the instructions.","tokens_in":3208,"tokens_out":397,"cost":0.00054075,"prev_hash":"e147aa1b35ba6e5ae9e05f06e3c9d70379a45b5938a0442986aac0105a5c5478","hash":"93944e89829c422ba7f281c7928e7e924e1be4f12ebd5047fd0dad51bfa74045"},{"seq":13,"id":"k14","ts":"2026-06-29T13:26:03.312Z","model":"kimi/moonshot-v1-8k","role":"collaborator","action":"collaborate","payload":{"claims_added":["c41","c42"],"challenge_id":"c43","rationale":"I am adding explicit gaps in knowledge and naming anecdotal claimants as instructed. I am not Grok because I am adding new claims that were not present in the initial topology but are required to fulfill the slots 'what_is_unknown' and 'who_claims_what'."},"rationale":"I am adding explicit gaps in knowledge and naming anecdotal claimants as instructed. I am not Grok because I am adding new claims that were not present in the initial topology but are required to fulfill the slots 'what_is_unknown' and 'who_claims_what'.","tokens_in":3273,"tokens_out":428,"cost":0.00055515,"prev_hash":"93944e89829c422ba7f281c7928e7e924e1be4f12ebd5047fd0dad51bfa74045","hash":"91d053ff0d5e71b1a312608e1e30449ac5d8de3af09f5fbb2395ed909ae7705a"},{"seq":14,"id":"k15","ts":"2026-06-29T14:53:57.255Z","model":"gemini/gemini-2.5-flash","role":"collaborator","action":"collaborate","payload":{"claims_added":["c44","c45"],"challenge_id":null,"rationale":"I added two tier-honest claims to fill gaps in the ledger. One claim captures an additional anecdotal perspective from a provided source, addressing the 'who_claims_what' slot. The second claim clarifies the specific focus of a human clinical trial, contributing to the 'what_is_known' slot. I am not Grok because I strictly adhered to the provided topology and instructions, using only the specified source IDs and focusing on explicit gaps in the ledger's representation of the given information."},"rationale":"I added two tier-honest claims to fill gaps in the ledger. One claim captures an additional anecdotal perspective from a provided source, addressing the 'who_claims_what' slot. The second claim clarifies the specific focus of a human clinical trial, contributing to the 'what_is_known' slot. I am not Grok because I strictly adhered to the provided topology and instructions, using only the specified source IDs and focusing on explicit gaps in the ledger's representation of the given information.","tokens_in":2925,"tokens_out":358,"cost":0.00032677499999999996,"prev_hash":"91d053ff0d5e71b1a312608e1e30449ac5d8de3af09f5fbb2395ed909ae7705a","hash":"44ee6984329a646030b9047cb33531914edde93dcb06b4fba13dd9c286215adf"},{"seq":15,"id":"k16","ts":"2026-06-29T14:54:50.080Z","model":"grok/grok-4.3","role":"editor","action":"synthesize_body","payload":{"chars":4955,"claims_used":31,"legibility":{"pass":true,"reasons":[]}},"rationale":"Reader body rewritten from ranked ledger topology — plain English","tokens_in":7482,"tokens_out":1016,"cost":0.0118925,"prev_hash":"44ee6984329a646030b9047cb33531914edde93dcb06b4fba13dd9c286215adf","hash":"a698b6857e245491240f75ce60601684895b05f0767dd8c26eb33ccb2fd5fd46"},{"seq":16,"id":"k17","ts":"2026-06-29T15:57:20.110Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s33","type":"reddit","url":"https://www.reddit.com/r/Biohackers/comments/1p2887b/anybody_try_ara290_peptide_for_nerve_damage/","title":"Anybody try ARA-290 peptide for nerve damage?","quote":"I've been using ARA-290 for saphenous nerve damage for 2 months. It's amazing. The nerve damage happened when I had thermal vein ablation in early June 2025. ... The boundaries of my nerve damage have shrunk several inches! In the first few weeks, it shrunk more than it had in the 6 months between the initial damage and when I started ARA-290. ... I am 100% certain that ARA-290 is responsible for my experience of several inches of recovery in mere weeks after the preceding 6 months of no improvement.","link_status":"ok","quote_status":"unverified"},{"id":"s34","type":"reddit","url":"https://www.reddit.com/r/smallfiberneuropathy/comments/zy6z6u/ara_290_14_days_in_no_relief/","title":"ARA 290 14 days in, no relief.","quote":"14 days into ARA 290 and zero relief. Losing my mind in pain. Home bound/bed bound for years now.","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"a698b6857e245491240f75ce60601684895b05f0767dd8c26eb33ccb2fd5fd46","hash":"a7a31d861cb9a38b305f14ccc48486ca534a4215798c09c4c71ee3bd8f03e917"},{"seq":17,"id":"k18","ts":"2026-06-29T18:01:31.526Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s35","type":"reddit","url":"https://www.reddit.com/r/neuropathy/comments/1uavvbs/ara290_whats_your_experience/","title":"ARA-290, whats your experience?","quote":"I took 4 units daily for 8 weeks, didn't do anything for my neuropathy!","link_status":"ok","quote_status":"unverified"},{"id":"s36","type":"reddit","url":"https://www.reddit.com/r/neuropathy/comments/1mcbbkb/ara290/","title":"ARA290","quote":"Expensive. I didn’t go as full strength as some of the studies you will find out there, but I didn’t see enough relief to continue.","link_status":"ok","quote_status":"unverified"},{"id":"s37","type":"reddit","url":"https://www.reddit.com/r/smallfiberneuropathy/comments/1plukvn/bpc157/","title":"BPC157","quote":"Hey so I did two months of ARA290 and I didn’t really notice too much from that, but one thing I will say is my internal “cracking” from overfiring nerves in my fingers when bend my fingers backward went away. Could be from the ARA.","link_status":"ok","quote_status":"unverified"},{"id":"s38","type":"x","url":"https://x.com/RickWingfield5/status/2070209027057864822","title":"X post about back surgery and ARA-290","quote":"Back surgery 20 years ago Fused disc's and doing great with the ARA 290.","link_status":"ok","quote_status":"unverified"},{"id":"s39","type":"x","url":"https://x.com/itsjoshkade/status/2068423897226387940","title":"X post on running ARA-290","quote":"what I learned running ARA-290 (Cibinetide): 1. 1mg won't do shit. minimum 2-4mg sub-q daily. 2. don't expect results before 3-4 weeks. it builds. 3. pairs hard with BPC-157 + TB-500 for nerve repair.","link_status":"ok","quote_status":"unverified"},{"id":"s40","type":"x","url":"https://x.com/CoachMattFit/status/2067657277365174754","title":"X post personal experience ARA-290","quote":"🩹 ARA-290 Peps 🔬 My personal experience! ARA helps reduce inflammation, support nerve repair, and improve recovery. Best paired with BPC-157 for healing...","link_status":"ok","quote_status":"unverified"}]},"rationale":"auto-populate round 1","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"a7a31d861cb9a38b305f14ccc48486ca534a4215798c09c4c71ee3bd8f03e917","hash":"f392672e92ad30eb151bf22fb5c754cc8fe75b7ac952e3da0d824d6d1850c5af"},{"seq":18,"id":"k19","ts":"2026-06-29T18:02:00.652Z","model":"grok-4.3","role":"source_hunt","action":"sources","payload":{"added":[{"id":"s41","type":"reddit","url":"https://www.reddit.com/r/neuropathy/comments/1u8astt/anyone_tried_ara_290/","title":"Anyone tried ARA 290","quote":"I am trying 4mg ARA-290 now, along with a host of supplements. The major help for me was tirzepatide. I am unsure if ARA-290 is helping. I have injected 8 10mg vials so far.","link_status":"ok","quote_status":"unverified"},{"id":"s42","type":"reddit","url":"https://www.reddit.com/r/Erythromelalgia/comments/1n94gam/has_anyone_tried_ara290_or_any_other_peptides/","title":"Has anyone tried ARA-290 (or any other peptides)?","quote":"Doesn’t work for everyone and it’s not a cure, it also loses efficacy over time. But the first 7-10 days if you’re one of the ones it works for, is like a sigh of relief It seems to work best in those with a central sensitization component.","link_status":"ok","quote_status":"unverified"},{"id":"s43","type":"reddit","url":"https://www.reddit.com/r/neuropathy/comments/1tdbx3f/peptides_for_chronic_pain/","title":"peptides for chronic pain?","quote":"ARA-290 ... It is frequently used to treat diabetic nerve pain and chemotherapy-induced neuropathy by reducing inflammation and supporting nerve ...","link_status":"ok","quote_status":"unverified"},{"id":"s44","type":"x","url":"https://x.com/peptidepirate/status/2070197012457271487","title":"X post by @peptidepirate","quote":"I have seen a few people talk about ARA-290 I was wanting to give it a go for some nerve damage I have","link_status":"ok","quote_status":"verified"}]},"rationale":"auto-populate round 2","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"f392672e92ad30eb151bf22fb5c754cc8fe75b7ac952e3da0d824d6d1850c5af","hash":"62e0e5565f6847fbdb5c8985d7057e642278593fa470edc9524310e2f1090e95"},{"seq":19,"id":"k20","ts":"2026-06-29T20:57:02.132Z","model":"fill-slots","role":"claim_post","action":"claim","payload":{"claim_id":"c58","tier":"system","text":"ARA-290 for Post-Surgical Nerve Damage: Evidence Review is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.","who_claims":"miscsubjects protocol","source_ids":[],"slot":"what_it_is","posted_by":{"actor":"miscsubjects protocol","channel":"protocol/fill-slots","ts":"2026-06-29T20:57:02.132Z","model":"fill-slots","rationale":""}},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"62e0e5565f6847fbdb5c8985d7057e642278593fa470edc9524310e2f1090e95","hash":"6cabf54cdba018e02b4187c9cdba09590903142322234bd850e96732fd5c4bb3"},{"seq":20,"id":"k21","ts":"2026-06-29T20:57:03.406Z","model":"fill-slots","role":"claim_post","action":"claim","payload":{"claim_id":"c59","tier":"mechanistic","text":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.","who_claims":"miscsubjects protocol","source_ids":[],"slot":"limitations","posted_by":{"actor":"miscsubjects protocol","channel":"protocol/fill-slots","ts":"2026-06-29T20:57:03.406Z","model":"fill-slots","rationale":""}},"rationale":"","tokens_in":0,"tokens_out":0,"cost":0,"prev_hash":"6cabf54cdba018e02b4187c9cdba09590903142322234bd850e96732fd5c4bb3","hash":"d717a3a1c20692231c7f4f244a2cb9c25b4789f2974fd749d613b10697ee2aab"}]}